Takhzyro™ (lanadelumab-flyo) – New orphan drug approval
August 23, 2018 - The FDA announced the approval of Shire’s Takhzyro (lanadelumab-flyo), for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients 12 years and older.
Download PDF
